DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Baselga J, Piccart M, Gnant M et al.
Minimal molecular alteration in PI3KCA, FGFR1 and CCND1 is associated with increased benefit from everolimus in hormone receptor-positive, HER2-advanced breast cancer: Insights from the BOLERO-2 trial.
Eur J Cancer 2013;
49: S404-S405
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.